Isis Spin-out Zyoxel Announces Global Launch of TissueFlex
10 March 2011
TissueFlex® addresses the missing link between conventional 2D assays and in vivo studies, providing a true three-dimensional (3D) platform for in vitro cultures with more in vivo-like behaviour to improve the predictivity of drug safety and efficacy testing.
Zyoxel was spun out to exploit this technology in 2009, having received £100K funding from the Oxford University Challenge Seed Fund, administered by Isis Innovation, followed by a £1m investment from Hong Kong based multinational CN Innovations Holdings.
Using a novel microbioreactor technology TissueFlex enables cells to grow as three-dimensional tissues instead of conventional single layers. This provides better and more reliable information in the drug discovery processes used by pharmaceutical, chemical and cosmetic companies.
Linda Naylor, Head of the Technology Transfer Group at Isis Innovation, commented “Zyoxel was launched with great potential to improve drug discovery processes, and we are delighted that the company has now achieved their goal of offering a commercial product to the market.”